Biomarkers Market by Type (Efficacy, Pharmacodynamics, Predictive), Product & Service (Consumables, Services, Software), Disease, Application - Global Forecast 2023-2030
The Biomarkers Market is projected to reach USD 153.67 billion by 2030 from USD 53.45 billion in 2022, at a CAGR of 14.10% during the forecast period.
Market Segmentation & Coverage:
This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Biomarkers Market.
- Based on Type, market is studied across Efficacy, Pharmacodynamics, Predictive, Prognostic, Safety, Surrogate, and Validation. The Efficacy commanded largest market share of 23.65% in 2022, followed by Validation.
- Based on Product & Service, market is studied across Consumables, Services, and Software. The Consumables commanded largest market share of 50.87% in 2022, followed by Services.
- Based on Disease, market is studied across Cancer, Cardiovascular Diseases, Immunological Diseases, Infectious Diseases, and Neurological Diseases. The Cancer commanded largest market share of 51.17% in 2022, followed by Neurological Diseases.
- Based on Application, market is studied across Diagnostic, Disease Risk Assessment, Drug Discovery & Development, and Personalized Medicine. The Diagnostic commanded largest market share of 39.73% in 2022, followed by Drug Discovery & Development.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 39.50% in 2022, followed by Europe, Middle East & Africa.
The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix is an indispensable tool for assessing the Biomarkers Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.
Market Share Analysis:
The Market Share Analysis offers invaluable insights into the vendor landscape Biomarkers Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.
Key Company Profiles:
The report delves into recent significant developments in the Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alto Neuroscience,Inc., APIS Assay Technologies Limited, Augurex Life Sciences Corp, Bio-Rad Laboratories, Inc., BioAgilytix, Biocrates Life Sciences AG, Biofourmis Inc., Biognosys AG, BIOINFRA Life Science Inc., BioStarks, BioVision Inc., Charles River Laboratories, Inc., Clarigent Corporation, EKF Diagnostics Holdings PLC, Elo Health, Inc., F. Hoffmann-La Roche, Ltd., Merck KgaA, Nightingale Health Plc, Owkin Inc., Owlstone Medical Limited, PerkinElmer, Inc., Personalis, Inc., Proteomedix AG, QIAGEN GmbH, Renalytix PLC, Siemens Healthcare GmbH, Sino Biological Inc., Thermo Fisher Scientific, Inc., and VivoSense, Inc..
The report offers valuable insights on the following aspects:
- Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
- Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
- Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
- Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
- Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast for the Biomarkers Market?
- Which products, segments, applications, and areas hold the highest investment potential in the Biomarkers Market?
- What is the competitive strategic window for identifying opportunities in the Biomarkers Market?
- What are the latest technology trends and regulatory frameworks in the Biomarkers Market?
- What is the market share of the leading vendors in the Biomarkers Market?
- Which modes and strategic moves are suitable for entering the Biomarkers Market?
Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Biomarkers Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing usage of biomarkers testing owing to monitor the treatment of chronic disease
- 5.1.1.2. Increasing biomarkers diagnostic application for personalized medicine
- 5.1.1.3. Rising research and development activities in biotechnology and pharmaceutical sector
- 5.1.2. Restraints
- 5.1.2.1. High cost associated with production and lengthy time process for biomarkers development
- 5.1.3. Opportunities
- 5.1.3.1. Recent advancements in the development of prognostic and diagnostic
- biomarkers for cancer treatments
- 5.1.3.2. Integration of advanced technologies to develop biomarkers that provide high accuracy
- 5.1.4. Challenges
- 5.1.4.1. Issues associated with collection and storage of samples in biomarkers
- procedures
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of COVID-19
- 5.5. Cumulative Impact of Russia-Ukraine Conflict
- 5.6. Cumulative Impact of High Inflation
- 5.7. Porter’s Five Forces Analysis
- 5.7.1. Threat of New Entrants
- 5.7.2. Threat of Substitutes
- 5.7.3. Bargaining Power of Customers
- 5.7.4. Bargaining Power of Suppliers
- 5.7.5. Industry Rivalry
- 5.8. Value Chain & Critical Path Analysis
- 5.9. Regulatory Framework
- 5.10. Client Customization
- 6. Biomarkers Market, by Type
- 6.1. Introduction
- 6.2. Efficacy
- 6.3. Pharmacodynamics
- 6.4. Predictive
- 6.5. Prognostic
- 6.6. Safety
- 6.7. Surrogate
- 6.8. Validation
- 7. Biomarkers Market, by Product & Service
- 7.1. Introduction
- 7.2. Consumables
- 7.3. Services
- 7.4. Software
- 8. Biomarkers Market, by Disease
- 8.1. Introduction
- 8.2. Cancer
- 8.3. Cardiovascular Diseases
- 8.4. Immunological Diseases
- 8.5. Infectious Diseases
- 8.6. Neurological Diseases
- 9. Biomarkers Market, by Application
- 9.1. Introduction
- 9.2. Diagnostic
- 9.3. Disease Risk Assessment
- 9.4. Drug Discovery & Development
- 9.5. Personalized Medicine
- 10. Americas Biomarkers Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Biomarkers Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Biomarkers Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
- 13.3.1. Merger & Acquisition
- 13.3.1.1. Theralink Acquires Immunotherapy Biomarker Patent From Vanderbilt University
- 13.3.1.2. Mainz Biomed Acquires Entire Intellectual Property Portfolio For Its Colorectal Cancer Diagnostic Test Program
- 13.3.2. Agreement, Collaboration, & Partnership
- 13.3.2.1. ObvioHealth Signs R&D Partnership with A*STAR to Identify and Develop Novel Digital Biomarkers
- 13.3.2.2. PrecisionLife Completes Agreement with King’s College London to Enable New Precision Neuroscience Treatments in MND/ALS
- 13.3.2.3. AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Strategic Partnership to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration
- 13.3.2.4. Vocal Biomarker Agreement Set To Benefit Patients With COPD in India
- 13.3.3. New Product Launch & Enhancement
- 13.3.3.1. Akoya Biosciences Launches PhenoCode Signature Panels to Accelerate Development of Predictive Biomarkers for Cancer Immunotherapy
- 13.3.4. Investment & Funding
- 13.3.4.1. Genialis Raises USD 13 Million to Build Clinical Biomarkers that Predict Patient Response
- 13.3.5. Award, Recognition, & Expansion
- 13.3.5.1. Abbott Receives FDA Clearance For First Commercially Available Lab-Based Blood Test To Help Evaluate Concussion
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. Abbott Laboratories
- 14.1.2. Alto Neuroscience,Inc.
- 14.1.3. APIS Assay Technologies Limited
- 14.1.4. Augurex Life Sciences Corp
- 14.1.5. Bio-Rad Laboratories, Inc.
- 14.1.6. BioAgilytix
- 14.1.7. Biocrates Life Sciences AG
- 14.1.8. Biofourmis Inc.
- 14.1.9. Biognosys AG
- 14.1.10. BIOINFRA Life Science Inc.
- 14.1.11. BioStarks
- 14.1.12. BioVision Inc.
- 14.1.13. Charles River Laboratories, Inc.
- 14.1.14. Clarigent Corporation
- 14.1.15. EKF Diagnostics Holdings PLC
- 14.1.16. Elo Health, Inc.
- 14.1.17. F. Hoffmann-La Roche, Ltd.
- 14.1.18. Merck KgaA
- 14.1.19. Nightingale Health Plc
- 14.1.20. Owkin Inc.
- 14.1.21. Owlstone Medical Limited
- 14.1.22. PerkinElmer, Inc.
- 14.1.23. Personalis, Inc.
- 14.1.24. Proteomedix AG
- 14.1.25. QIAGEN GmbH
- 14.1.26. Renalytix PLC
- 14.1.27. Siemens Healthcare GmbH
- 14.1.28. Sino Biological Inc.
- 14.1.29. Thermo Fisher Scientific, Inc.
- 14.1.30. VivoSense, Inc.
- 14.2. Key Product Portfolio
- 15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook